David A. Smith

4.0k citations

53 papers · 1.5k indexed · 1 hit paper · h-index 19

Impact in

Gastroenterology top 2%
- Gastrointestinal Tumor Research and Treatment
Hepatology top 5%
- Hepatitis C virus research

Papers in

Hepatology 10
- Hepatitis C virus research 10
Occupational Therapy 2

Co-authors: Thomas G. Lowe Michael O’Brien A. David Tahernia Sarah Slater Wasat Mansoor David Cunningham David Ferry David González
Journals: Journal of Clinical Oncology (5 papers)Journal of the American Medical Directors Association (4 papers)Spine (4 papers)Journal of Hepatology (2 papers)Blood (1 paper)
Partner nations: United Kingdom United States Switzerland

In The Last Decade

David A. Smith

52 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial 2013 · 547 citations

Peers

Countries citing papers authored by David A. Smith

Since Specialization

Citations

This map shows the geographic impact of David A. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Smith more than expected).

Fields of papers citing papers by David A. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Smith. The network helps show where David A. Smith may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David A. Smith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David A. Smith Line = papers co-authored together David A. Smith links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis Expert Review of Vaccines ·Alberto San Francisco Ramos, Xuexu Chen, Livia Chiu, David A. Smith, Natasha Thorn, Eva Galiza, Hisami Hasegawa, Jennifer Pearce, 杨聪敏, Catherine Cosgrove, Yingfen Hsia, Paul T. Heath	2024	7
2	Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy Journal of Viral Hepatitis ·David A. Smith, Daniel Bradshaw, Jean L. Mbisa, Carmen F. Manso, David Bibby, Joshua B. Singer, Emma C. Thomson, Ana da Silva Filipe, Elihú Aranday-Cortés, M. Azim Ansari, Anthony Brown, Emma Hudson, Alzamora Flores, Brendan Healy, Batuhan Berk Çetin, John McLauchlan, Eleanor Barnes, William L. Irving	2021	19
3	Longitudinal Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized Patients With Corona Virus Disease 2019 Hepatology Communications ·Tingyan Wang, David A. Smith, Cori Campbell, Steve Harris, Hizni Salih, С. В. Зайцев, Kerrie Woods, 淳平大森, Oliver Freeman, Jeannette Norris, Thomas Marjot, Gwilym J. Webb, Jim Davies, Eleanor Barnes, Philippa C. Matthews	2021	6
4	Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia Journal of Hepatology ·Dung Nguyen, David A. Smith, 一民西宮, Andrea Magrì, Eleanor Barnes, Peter Simmonds	2020	23
5	Interpreting Viral Deep Sequencing Data with GLUE Viruses ·Joshua B. Singer, Emma C. Thomson, Joseph Hughes, Elihú Aranday-Cortés, John McLauchlan, Ana da Silva Filipe, L. Tong, Carmen F. Manso, Robert J. Gifford, David L. Robertson, Eleanor Barnes, M. Azim Ansari, Jean L. Mbisa, David Bibby, Daniel Bradshaw, David A. Smith	2019	17
6	Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome American Journal of Nephrology ·Monique E. Cho, Mary H. Branton, David A. Smith, Henri Pouctal, Lilian Howard, James C. Reynolds, Donald L. Rosenstein, Sanjeev Sethi, Gabriel A. Pinheiro, Laura Barisoni, Fernando C. Fervenza, Jeffrey B. Kopp	2019	3
7	Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir Gastroenterology ·Peter A. C. Wing, Meleri Jones, Michelle Cheung, Hanbo GAO, Connor Bamford, Wing-Yiu Jason Lee, Elihú Aranday-Cortés, Ana da Silva Filipe, John McLauchlan, David A. Smith, William L. Irving, Morven Cunningham, M. Azim Ansari, Eleanor Barnes, Graham R. Foster	2019	19
8	Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse Infection and Drug Resistance ·David Bonsall, Stuart Black, Anita Y. M. Howe, Robert A. Chase, Paul Ingravallo, George Mantalos, Anthony Brown, David A. Smith, Rory Bowden, Eleanor Barnes	2018	7
9	nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC Frontiers in Oncology ·Corey J. Langer, Edward S. Kim, Eric Anderson, Robert M. Jotte, Manuel Modiano, Daniel Haggstrom, Gourab Kalita, David A. Smith, Christopher Dakhil, Kartik Konduri, Tymara Berry, Teng Jin Ong, Alexandra Sanford, Katayoun I. Amiri, Jonathan W. Goldman, Jared Weiss, (unknown)	2018	7
10	Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors Hepatology ·David A. Smith, Andrea Magrì, David Bonsall, Camilla L. C. Ip, Amy Trebes, Anthony Brown, 高橋賢一, Rory Bowden, Dung Nguyen, M. Azim Ansari, Peter Simmonds, Eleanor Barnes	2018	50
11	A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia Journal of Hematology & Oncology ·Saroj Vadhan‐Raj, Rafat Abonour, Jonathan W. Goldman, David A. Smith, Christopher A. Slapak, Robert Ilaria, Ramón V. Tiu, Xuejing Wang, Sophie Callies, Joanne Cox, Jay Tuttle, Y Akyurekli, Eric Roeland	2017	75
12	Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy Cancer Immunology Immunotherapy ·David A. Smith, Paul Conkling, Donald Richards, John Nemunaitis, Thomas E. Boyd, Alain C. Mita, Guillaume de La Bourdonnaye, David Wages, Alice Bexon	2014	58
13	Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial The Lancet Oncology ·Thomas K. Waddell, Ian Chau, David Cunningham, David González, Alicia Okines, Andrew Wotherspoon, Claire Saffery, Gary Middleton, Jonathan Wadsley, David Ferry, Wasat Mansoor, Tom Crosby, Fareeda Y. Coxon, David A. Smith, Justin S. Waters, Timothy Iveson, Stephen Falk, Sarah Slater, Clare Peckitt, Yolanda Barbáchano Hit paper breakdown →	2013	547
14	Single-Rod Versus Dual-Rod Anterior Instrumentation for Idiopathic Scoliosis Spine ·Thomas G. Lowe, Hasan Çotuk, David A. Smith, Meetztli Alejandra Valencia-Vargas, Gabriel Delon, Michael O’Brien, Mahasin Martinson, Lucas A. Wilson, Hong Mei-yun	2005	18
15	Characterisation of a new gene and genomic analysis of the cluster FEMS Microbiology Letters ·Carlos H.I. Ramos, Rhea Thomas, David A. Smith, Sílvia Reni Bortolin Uliana	2004	2
16	Anterior Single Rod Instrumentation for Thoracolumbar Adolescent Idiopathic Scoliosis With And Without the Use of Structural Interbody Support Spine ·Thomas G. Lowe, Fatima Al-batool Sartawe, David A. Smith, Michael O’Brien, Arumega Zaferar, Iuliia Gafarova	2003	36
17	Platelet Calmodulin Levels in Adolescent Idiopathic Scoliosis Spine ·Thomas G. Lowe, David W. Lawellin, David A. Smith, Charles T. Price, Thomas R. Häher, Andrew Merola, M D O’Brien	2002	55
18	Unilateral Transforaminal Posterior Lumbar Interbody Fusion (TLIF): Indications, Technique, and 2-Year Results Journal of Spinal Disorders & Techniques ·Thomas G. Lowe, A. David Tahernia, Michael O’Brien, David A. Smith	2002	184
19	Is admission after intravenous heroin overdose necessary? Annals of Emergency Medicine ·David A. Smith, J.J Moreno Sada, Von Hildebrand, Donald M. Yealy	1992	42
20	Treatment of Diamond‐Blackfan anaemia with haematopoietic growth factors, granulocyte‐macrophage colony stimulating factor and interleukin 3: sustained remissions following IL‐3 British Journal of Haematology ·Cynthia E. Dunbar, David A. Smith, Janice Kimball, Leslie Garrison, X. Y. Lee, Neal S. Young	1991	41

About David A. Smith

David A. Smith is a scholar working on Hepatology, Occupational Therapy, Pathology and Forensic Medicine, Infectious Diseases and Genetics, having authored 53 papers that have together received 1.5k indexed citations. Recurring topics across this work include Hepatitis C virus research (10 papers), Hepatitis B Virus Studies (7 papers), Liver Disease Diagnosis and Treatment (7 papers), Spine and Intervertebral Disc Pathology (5 papers), HIV/AIDS drug development and treatment (4 papers), Lung Cancer Treatments and Mutations (4 papers), Spinal Fractures and Fixation Techniques (4 papers) and Scoliosis diagnosis and treatment (4 papers). The work is most often cited by research in Gastroenterology (181 citations), Hepatology (170 citations), Pathology and Forensic Medicine (350 citations), Pulmonary and Respiratory Medicine (506 citations) and Oncology (420 citations). David A. Smith has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Thomas G. Lowe, Michael O’Brien, A. David Tahernia, Sarah Slater, Wasat Mansoor, David Cunningham, David Ferry, David González, Timothy Iveson and Alicia Okines. Their work appears in journals such as Journal of Clinical Oncology, Journal of the American Medical Directors Association, Spine, Journal of Hepatology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact